暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
PDSB240517C2500
- 0.85
- -0.15-15.00%
延時15分鐘行情交易中 05/17 13:49 (美東)
1.00最高價0.85最低價
1.00今開1.00昨收111張成交量397張未平倉合約數2.50行權價1.11萬成交額0.00%引伸波幅-0.99%溢價2024/05/17到期日1.04内在价值100合約乘數0天距到期日0.00時間價值100合約規模美式期權類型--Delta--Gamma3.54槓桿倍數--Theta--Rho--有效槓桿--Vega
分時
- 5日
- 日K
新聞
“PDS Biotech 的生存益處被誇大了” ——作者：Adam Feuerstein/ STAT News
這是Adam's Biotech Scorecard的在線版本，這是一份新的僅限訂閱者的時事通訊。STAT+ 訂閱者可以在這裏註冊，以便每週四將其發送到他們的收件箱。你好，朋友們！我在 Sa
PDS Biotechnology | 10-Q：季度報表
由於財務狀況強勁，臨床產品線前景看好，PDS生物技術的買入評級得到確認
快訊 | PDS Biotechnology 2024年第一季度GAAP每股收益美元（0.30）超過預期（0.37），現金6,660萬美元
快訊 | PDS Biotech提供業務最新情況並報告2024年第一季度財務業績
快訊 | PDS Biotechnology第一季度淨收入爲-1,060萬美元
評論
$PDS Biotechnology(PDSB.US$ PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints
1
$PDS Biotechnology(PDSB.US$
NEWS
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYT...
NEWS
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYT...
1
閱讀更多